{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:37:10Z","timestamp":1792859830952,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Department of OTO-HNS, University of Maryland SOM"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.imbio.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T10:44:17Z","timestamp":1551523457000},"page":"362-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["NK cell expression of Tim-3: First impressions matter"],"prefix":"10.1016","volume":"224","author":[{"given":"Edward C.","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Khaladj-Ghom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Burch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soren","family":"Bentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronna","family":"Hertzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Strome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2019.03.001_bib0005","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0010","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2019.03.001_bib0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/imr.12606","article-title":"The family of the interleukin-1 receptors","volume":"281","author":"Boraschi","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.imbio.2019.03.001_bib0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/imm.12463","article-title":"MicroRNA-155 regulates interferon-\u03b3 production in natural killer cells via Tim-3 signalling in chronic hepatitis C virus infection","volume":"145","author":"Cheng","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.imbio.2019.03.001_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0035","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Cutsem","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"da Silva","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.imbio.2019.03.001_bib0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation","volume":"108","author":"De Maria","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imbio.2019.03.001_bib0050","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4049\/jimmunol.180.2.850","article-title":"Regulatory NK cells suppress antigen-specific t cell responses","volume":"180","author":"Deniz","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0055","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.imbio.2019.03.001_bib0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI16015","article-title":"Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis","volume":"111","author":"Dong","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2019.03.001_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Autoimmun. Highlights"},{"key":"10.1016\/j.imbio.2019.03.001_bib0070","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clim.2015.03.008","article-title":"Hepatitis C viral infection is associated with activated cytolytic natural killer cells expressing high levels of T cell immunoglobulin- and mucin-domain-containing molecule-3","volume":"158","author":"Golden-Mason","year":"2015","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0080","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2019.03.001_bib0085","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2009.12.005","article-title":"T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B","volume":"52","author":"Ju","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0090","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-11-253286","article-title":"CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells","volume":"116","author":"Juelke","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0095","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI61226","article-title":"Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer","volume":"122","author":"Kohrt","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2019.03.001_bib0100","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1172\/JCI73014","article-title":"Targeting CD137 enhances the efficacy of cetuximab","volume":"124","author":"Kohrt","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imbio.2019.03.001_bib0105","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nri2366","article-title":"New roles for TIM family members in immune regulation","volume":"8","author":"Kuchroo","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2007-11-122465","article-title":"Fc-dependent expression of CD137 on human NK cells: insights into \u201cagonistic\u201d effects of anti-CD137 monoclonal antibodies","volume":"112","author":"Lin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0952-7915(98)80165-9","article-title":"JAK\/STAT signaling by cytokine receptors","volume":"10","author":"Liu","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0120","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ni0905-868","article-title":"NK cell tolerance: revisiting the central dogma","volume":"6","author":"MacDonald","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0125","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2004-07-2782","article-title":"Stabilization of IFN-\u03b3 mRNA by MAPK p38 in IL-12\u2013 and IL-18\u2013stimulated human NK cells","volume":"105","author":"Mavropoulos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2019.03.001_bib0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2019.03.001_bib0140","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/mabs.2.1.10789","article-title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology","volume":"2","author":"Oflazoglu","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.imbio.2019.03.001_bib0150","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imbio.2019.03.001_bib0155","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ctrv.2015.05.007","article-title":"Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas","volume":"41","author":"P\u00e9rez-Callejo","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.imbio.2019.03.001_bib0160","doi-asserted-by":"crossref","first-page":"17049","DOI":"10.1038\/s41598-017-17255-8","article-title":"Multivalent Fc\u03b3-receptor engagement by a hexameric Fc-fusion protein triggers Fc\u03b3-receptor internalisation and modulation of Fc\u03b3-receptor functions","volume":"7","author":"Qureshi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imbio.2019.03.001_bib0165","first-page":"203","article-title":"Rituximab resistance. Best practice & research","volume":"24","author":"Rezvani","year":"2011","journal-title":"Clin. Haematol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0170","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/ni987","article-title":"Tim-3 inhibits T helper type 1\u2013mediated auto- and alloimmune responses and promotes immunological tolerance","volume":"4","author":"S\u00e1nchez-Fueyo","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0175","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/10428190902878471","article-title":"Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention AU - Stolz","volume":"50","author":"Stolz","year":"2009","journal-title":"Claudia. Leuk. Lymphoma"},{"key":"10.1016\/j.imbio.2019.03.001_bib0180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2017.08.004","article-title":"Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease","volume":"84","author":"Sun","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.imbio.2019.03.001_bib0185","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00262-008-0613-3","article-title":"Fc\u03b3RIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck","volume":"58","author":"Taylor","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imbio.2019.03.001_bib0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.imbio.2019.03.001_bib0195","first-page":"6","article-title":"Nk cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","author":"Wang","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cyto.2015.05.012","article-title":"Tim-3 pathway affects NK cell impairment in patients with active tuberculosis","volume":"76","author":"Wang","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.imbio.2019.03.001_bib0205","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/eji.201190035","article-title":"Cancer immunotherapy: progress and challenges in the clinical setting","volume":"41","author":"Zarour","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0210","first-page":"241","article-title":"The regulatory effect of natural killer cells: do \"NK-reg cells\" exist?","volume":"3","author":"Zhang","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.imbio.2019.03.001_bib0215","first-page":"4","article-title":"A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity","author":"Zhang","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.imbio.2019.03.001_bib0220","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2016001917","article-title":"A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b","volume":"1","author":"Zhou","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.imbio.2019.03.001_bib0225","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298519300762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298519300762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:46:08Z","timestamp":1759250768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298519300762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0171298519300762"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2019.03.001","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NK cell expression of Tim-3: First impressions matter","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}